{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:30:05Z","timestamp":1781299805518,"version":"3.54.1"},"reference-count":67,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"AbbVie"},{"name":"AnaptysBio"},{"name":"Bristol-Myers Squibb"},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"EliLilly"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK-Stiefel"},{"DOI":"10.13039\/100015756","name":"Janssen-Cilag","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023331","name":"Leo-Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck"},{"name":"Novartis"},{"name":"PharmaEssentia"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sanofi"},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016879","name":"Union Chimique Belge","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016879","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.2217\/imt-2023-0139","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T09:34:36Z","timestamp":1702978476000},"page":"115-130","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-8718","authenticated-orcid":false,"given":"Tyng-Shiuan","family":"Hsieh","sequence":"first","affiliation":[{"name":"Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, 10002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, 10002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"2","key":"e_1_3_6_3_1","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman DD","year":"2005","unstructured":"Gladman DD , Antoni C , Mease P , Clegg DO , Nash P . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64(Suppl. 2), ii14\u201317 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.003"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105469"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"issue":"6","key":"e_1_3_6_10_1","first-page":"609","article-title":"Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs","volume":"15","author":"Spadaro A","year":"1997","unstructured":"Spadaro A , Taccari E , Mohtadi B , Riccieri V , Sensi F , Zoppini A . Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin. Exp. Rheumatol. 15(6), 609\u2013614 (1997).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220315"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0670"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00903-5"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210076"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14926"},{"issue":"5","key":"e_1_3_6_16_1","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian E","year":"2022","unstructured":"Sbidian E , Chaimani A , Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 5(5), CD011535 (2022).","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0011-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.8.892"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"issue":"3","key":"e_1_3_6_20_1","first-page":"378","article-title":"Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events","volume":"56","author":"Quach LT","year":"2017","unstructured":"Quach LT , Chang BH , Brophy MT , Soe Thwin S , Hannagan K , O\u2019Dell JR . Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. Rheumatology 56(3), 378\u2013383 (2017).","journal-title":"Rheumatology"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002336"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00300-4"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23255"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_3_6_25_1","unstructured":"Higgins JPT Thomas J Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). John Wiley & Sons Chichester UK (February 2022). www.training.cochrane.org\/handbook"},{"issue":"5","key":"e_1_3_6_26_1","first-page":"728","article-title":"The effectiveness of leflunomide in psoriatic arthritis","volume":"32","author":"Asiri A","year":"2014","unstructured":"Asiri A , Thavaneswaran A , Kalman-Lamb G , Chandran V , Gladman DD . The effectiveness of leflunomide in psoriatic arthritis. Clin. Exp. Rheumatol. 32(5), 728\u2013731 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024463"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201408"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05894-2"},{"key":"e_1_3_6_30_1","first-page":"116","article-title":"Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study","volume":"186","author":"Mazzanti G","year":"1994","unstructured":"Mazzanti G , Coloni L , De Sabbata G , Paladini G . Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm. Venereol. Suppl. 186, 116\u2013117 (1994).","journal-title":"Acta Derm. Venereol. Suppl."},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00028-5"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30339-8"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab905"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2534-x"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00137.x"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328329c79d"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)81244-3"},{"key":"e_1_3_6_38_1","unstructured":"FDA medication indication. https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/search (search date: 2024\/11\/28)."},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02976.x"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200105000-00002"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.08.025"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1236"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2014.08.009"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152840"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.157"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1512404"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_22_19"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000806"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16665330"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2012.08.002"},{"issue":"5","key":"e_1_3_6_55_1","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian E","year":"2022","unstructured":"Sbidian E , Chaimani A , Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 5(5), CD011535 (2022).","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.4.1581"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130078"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0835-9"},{"issue":"3","key":"e_1_3_6_59_1","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs \u2013 comparison of drugs and adverse reactions","volume":"35","author":"Helliwell PS","year":"2008","unstructured":"Helliwell PS , Taylor WJ , Group CS . Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs \u2013 comparison of drugs and adverse reactions. J. Rheumatol. 35(3), 472\u2013476 (2008).","journal-title":"J. Rheumatol."},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.7"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02239195"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05433-5"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.8.955"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34627"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00713-1"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20947296"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050571"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.03.002"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2023-0139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:32:17Z","timestamp":1715952737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2023-0139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.2217\/imt-2023-0139"],"URL":"https:\/\/doi.org\/10.2217\/imt-2023-0139","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}